# US 11,079,395 B2 · Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,079,395 B2
- Document ID: US11079395B2
- Status: Granted
- Kind: B2
- Application number: 16/805,136
- Filed: 2020-02-28
- Published: 2020-09-03
- Granted: 2021-08-03
- Earliest claimed: 2019-03-01
- Assignees: Abbott Laboratories; Emory University
- Applicants: Abbott Laboratories; Emory University
- Inventors: Agim Beshiri; Arshed A. Quyyumi
- Web page: https://patentgrep.com/patent/US11079395B2

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N 2800/50: Determining the risk of developing a disease
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Provided herein are methods for predicting or determining whether a subject with coronary artery disease is likely to experience or develop a major adverse cardiovascular event (MACE) based on determining cardiac troponin (cTnI) levels in a human at rest and during or after exercise.

## Claims

### Claim 1

A method comprising:
(a) detecting a resting level of cardiac troponin I (cTnI) of at least 4 ng/mL in a blood, serum, or plasma sample obtained from a human with coronary artery disease (CAD),
(b) detecting the level of cTnI in a blood, serum, or plasma sample obtained from the human during or after exercise,
(c) measuring at least a 10% increase in the cTnI level during or after exercise as compared the resting cTnI level, which indicates that the human is likely to experience a major adverse cardiovascular event (MACE), and
(d) administering to the human a therapeutically effective amount of at least one statin, at least one β-blocker, at least one nitrate, at least one phosphodiesterase (PDE) inhibitor, at least one calcium channel blocker, at least one cGMP stimulator, at least one sinus node inhibitor, at least one Rho kinase inhibitor, arginine, allopurinol, testosterone, or any combinations thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the human has stable coronary artery disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein the level of cTnI is detected using a high sensitivity cardiac troponin I assay.

### Claim 4 (depends on 3)

The method of claim 3, wherein the high sensitivity cardiac troponin I assay is an immunoassay, a clinical chemistry assay, a point-of-care assay, or a single molecule detection assay.

### Claim 5 (depends on 1)

The method of claim 1, wherein (b) comprises detecting the level of cTnI in a sample obtained from the human during exercise.

### Claim 6 (depends on 1)

The method of claim 1, wherein (b) comprises detecting the level of cTnI in a sample obtained from the human after exercise.

### Claim 7 (depends on 6)

The method of claim 6, wherein the sample is obtained from the human about 45 minutes after exercise.

### Claim 8 (depends on 1)

The method of claim 1, wherein the human has exercise-induced myocardial ischemia.

### Claim 9 (depends on 1)

The method of claim 1, which comprises measuring at least a 20% increase in the cTnI level during or after exercise as compared the cTnI level at rest.